TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04607356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Description: The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
Study: NCT06234566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dental implant surgery
Description: It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Speed Drilling Without Irrigation
Description: It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
Study: NCT04607356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-informed care
Description: Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
Study: NCT05324774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW0813
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously.
Study: NCT06090227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Standard of Care
Description: Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Standard of Care
Description: Administration of daily placebo tablets with standard of care for 6 months.
Study: NCT06235086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: TG103 injection, 7.5mg, 15 mg, SC, once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: TG103 injection, 7.5mg, 15 mg, SC, once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide, SC, once a week
Study: NCT05248633

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy with a dose of 40-50 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy with a dose of 40-50 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg d1,8,15,22
Study: NCT05740943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
Study: NCT05973422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIGI Insulin Management System
Description: Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
Study: NCT04795674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWM Training
Description: Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Training
Description: Computerized tasks with comparable engagement that do not tap executive working memory processes
Study: NCT03952416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation (EMR)
Description: EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity).
Study: NCT05842252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: greater trochanter transfer, subtrochanteric valgus osteotomy
Description: greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate
Study: NCT06262113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters about NF1 Care (Content Type 1)
Description: Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters about NF1 Care (Content Type 2)
Description: Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
Study: NCT05637827

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in each group, and only the natural development was observed

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in each group, and only the natural development was observed

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in each group, and only the natural development was observed
Study: NCT05373264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Description: An oral capsule containing 25mg of hydrochlorothiazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching oral capsule containing placebo
Study: NCT06122974

Intervention type: DEVICE
Group type: OTHER
Intervention: Drug Eluting Temporary Spur Stent System
Description: The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Transluminal Balloon Angioplasty
Description: A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
Study: NCT06584045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calculus bovis sativus (CBS)
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calculus bovis sativus (CBS)
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Study: NCT05275101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Response Planning
Description: Individuals complete an experimental collaborative suicide intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Risk Counseling
Description: Individuals complete a standard crisis risk management intervention.
Study: NCT04854096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-018
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Active Comparator
Study: NCT04633928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-TEC: Autologous nasal chondrocytes and ECM proteins
Description: Cells expanded in vitro and cultured in a collagen type I//III scaffold
Study: NCT06255652

Intervention type: DRUG
Intervention: Cephradin
Description: Velosef
Study: NCT06249282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study: NCT06239727

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced-dose Intensity-modulated radiotherapy
Description: 1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional-dose Intensity-modulated radiotherapy
Description: 1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F.
Study: NCT06249282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study: NCT06239727

Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional-dose Intensity-modulated radiotherapy
Description: 1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F.
Study: NCT04800146

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
Study: NCT06273228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up Online
Description: This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
Study: NCT04800146

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
Study: NCT04991129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 5mg QD: WJ01024, Q4W, once per day
Study: NCT06079047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group Dexamethasone
Description: Adductor canal block with dexamethasone
Study: NCT06115928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants will perform cardiac rehabilitation with hardware-type technology consisting of a PICO 4® head mounted display (HMD) headset and the software TREADMILL XR®.
Study: NCT04991129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 5mg BID: WJ01024, Q4W, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 10mg BID: WJ01024, Q4W, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 40mg BIW: WJ01024, Q4W, twice per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 60mg BIW: WJ01024, Q4W, twice per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 80mg BIW: WJ01024, Q4W, twice per week
Study: NCT06539715

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual field assessment
Description: Automated perimetry

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual field assessment
Description: Automated perimetry
Study: NCT04991129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 60mg QW: WJ01024, Q4W, once per week
Study: NCT06539715

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual field assessment
Description: Automated perimetry
Study: NCT06239727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (100 mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin (100 mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Study: NCT06238544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 tablets
Description: HRS-5965 tablets until the end of study treatment
Study: NCT04991129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 80mg QW: WJ01024, Q4W, once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 50mg QW: WJ01024, Q4W, once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01024
Description: 40mg QW: WJ01024, Q4W, once per week
Study: NCT05670470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0303
Description: Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orafang Tab
Description: Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
Study: NCT06239727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
Study: NCT05387889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation for Pulmonary Hypertension (MMPH)
Description: Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation for Pulmonary Hypertension (MMPH)
Description: Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.
Study: NCT06221852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic diet
Description: The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Guidelines for Americans
Description: Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).
Study: NCT06424756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
Study: NCT06079047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: group Controle
Description: Adductor canal block with saline solution
Study: NCT06487793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Insomnia Coach
Description: The intervention combines the Insomnia Coach app with additional brief alcohol intervention to facilitate behavior change for both drinking behavior and insomnia symptoms. Insomnia Coach contains multiple components of CBT-I (e.g., stimulus control, cognitive restructuring, relaxation training, sleep hygiene/psychoeducation, monitoring of sleep via journals). The brief alcohol intervention content added to the CBT-I app is based on CBT skills for moderate drinking, delivered in a motivational enhancement style, and has demonstrated efficacy among young adults and veterans (e.g., correcting perceived norms, use of protective behavioral strategies, challenging expectancies).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene comparator
Description: Content is based on sleep hygiene practices, but without additional CBT-I content featured in the experimental condition. There is also not brief alcohol intervention content in the control condition.
Study: NCT06424756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MitoQ matched Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MitoQ matched Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoTempo
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoTempo
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tempol
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tempol
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NAME
Description: During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NAME
Description: During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP - Sodium Nitroprusside
Description: At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP - Sodium Nitroprusside
Description: At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.
Study: NCT06464081

Intervention type: OTHER
Intervention: Sleep quality assessment
Description: 1. Pediatric Sleep Questionnaire.

Intervention type: OTHER
Intervention: Anthropometry
Description: 2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate The measures 2.3 and 2.4 will be realized via the Quick Tongue-Tie assessment tool

Intervention type: OTHER
Intervention: Tongue strength assessment
Description: 3. Tongue pressure while swallowing. 4. Tongue peak pressure during tongue elevation. 5. Tongue peak pressure during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device.

Intervention type: OTHER
Intervention: Tongue endurance assessment
Description: 6. The tongue endurance during tongue elevation. 7. The tongue endurance during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device and a timer.

Intervention type: OTHER
Intervention: Orofacial praxis assessment
Description: 8. Motricité Bucco-Linguo-Faciale (MBLF) test.
Study: NCT06559033

Intervention type: BIOLOGICAL
Intervention: Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
Description: Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.

Intervention type: BIOLOGICAL
Intervention: Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
Description: Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.

Intervention type: BIOLOGICAL
Intervention: Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
Description: Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.